🎥 Although the EASD Early Career Academy’s "Best of EASD 2025" series has now come to an end, the conversation continues.
In the final episode, Dr Sergio Di Molfetta (Società Italiana di Diabetologia) shares his key takeaways from #EASD2025, focusing on #CGM & #AID.
🔗👉 youtu.be/2tng_89XvjI?...
🎬Episode 7 of Best of #EASD2025 is live! Dr. Michael Leutner (Medical University of Vienna) shares his key highlights, focusing on the SOUL trial and new insights into #HeartFailure and peripheral artery disease in #T2D.
🎥Watch👉 youtu.be/EgoIFh2bT-M?...
#Diabetes #DiabetesResearch
From #EASD2025 - #Tirzepatide is noninferior to #dulaglutide for protecting against cardiovascular events in people with type 2 diabetes and atherosclerotic cardiovascular disease.
👉 buff.ly/mzd96B5
#MedNews
🎬Episode 6 of the Best of EASD 2025 series is now live!
For the final episode of our Best of EASD 2025 series this year, we invited Romane Lartigue to share her personal highlights from her first EASD Annual Meeting.
Watch here👉 youtu.be/w-QVVyeesro
Stay tuned for more!
#EASD2025 #Networking
A red graphic titled “Best of EASD 2025 by the EASD Early Career Academy.” On the left, a white outline of a Ferris wheel extends across the background. Below it, there is a circular photo of a man with short dark hair, wearing a dark jacket, standing outdoors with blurred trees behind him. To the right of the photo, blue text reads “featuring… Sindre Lee-Ødegård, Norway” and “highlighting… From insulin resistance to heart health.” In the lower right corner is the EASD 2025 Vienna logo.
🎧 Hear Dr Sindre Lee-Ødegård break down his top highlights from #EASD2025 in the latest "Best of EASD 2025" ep. From #PrecisionMedicine in monogenic #diabetes to tissue-specific insulin resistance, new #GLP-1 data & the impact of #diabetes distress.
👉 Watch now: www.youtube.com/watch?v=JVg9...
Dr Raphael Scharfmann speaking into a microphone during an interview at EASD2025 in Vienna. The image is framed with blue circular graphics and the EASD logo. Text on the image reads: “Pancreas development - key to unexpected diabetes treatments."
🎙️ Weekend listening recommendation!
At #EASD2025, Prof. Raphael Scharfmann (@inserm.fr) was awarded the 19th Albert Renold Prize for his work on beta cells & type 1 diabetes. From stem cell advances to measuring beta cell mass in humans - a must-listen!
🎧Listen now 👉 www.easd.org/media-centre...
A group of four people sit in chairs having a panel discussion, holding blue microphones, in front of a wooden wall. The design overlay includes the EASD logo and a soundwave graphic. Text reads: “Rising Stars: the future of diabetes research.
🎙️ New #podcast episode out now!
Listen to the #easd2025 Rising Stars in #diabetes #research - Four young scientists shaping the future of diabetes share what drives their research & their hopes for the next decade in diabetes science.
🎧👉 Listen now: www.easd.org/mediacentre/...
❗️Te esperamos‼️🗓️ Martes, 28 de octubre de 2025 en nuestro Webinar
⚠️Novedades presentadas en el Congreso Europeo de Diabetes (EASD)
No te pierdas las últimas actualizaciones en el manejo de la #diabetes compartidas en el #EASD2025
¡Inscríbete ya! 👇🏼
app.bipeek.com/registro-event…
Graphic announcing CME certificates for the 61st EASD Annual Meeting. The banner features a red background with blue and white text reading: ‘61st EASD Annual Meeting, 15 - 19 September 2025, Vienna, Austria.’ Below, a white and blue section says: ‘Now available - CME Certificates. EASD 2025 participants can now download their EACCME Certificate.’ The EASD 2025 Vienna logo appears in the top left corner, and the EASD logo with website easd.org is at the bottom.
📜 Certificates Now Available!
#easd2025 registered participants can now download their EACCME certificates as well as their Certificates of Attendance for the Annual Meeting directly from their #MyEASD account.
🔗👉 For more, visit: www.easd.org/annual-meeti...
#Diabetes #Certification #CME
🙌The report of the IDF Europe symposium at #EASD2025 is out!
💡During the event, experts and people living with #T1D & #T2D discussed why integrated care is key to overcoming fragmented systems and improving #diabetes management.
➡️Read it here: idf.org/europe/media...
Stylized graphic featuring overlapping circular shapes in light blue and white, framing screenshots of the EASD (European Association for the Study of Diabetes) Media Centre website. The website interface displays various publication covers from past years, a world map of viewer locations, and media content. The background is a gradient of blue tones.
🎥 Missed the #EASD2025 Annual Meeting in Vienna?
All presentations & webcasts are now available for free in our EASD Media Centre.
Explore the latest insights in #diabetes #research & catch up on the latest breakthroughs shaping the future of Diabetes #care 🔬
👉 www.easd.org/media-centre...
Sinocare Showcases Its Comprehensive Diabetes Management Solutions at EASD #DiabetesManagement #DiabetesCare #EASD2025 #HealthTech #CGM
⏰ The #EASD2025 Virtual Meeting Platform (VMX) closes on 17 October 2025! Last chance to catch up on the groundbreaking science & earn #CME credits.
Enjoy a look at #easd2025 by the numbers👇
Log in with your MyEASD credentials before it closes - virtualcongress.easd.org
#medicaleducation
🗣️ Have your say! The panel is welcoming feedback from the public.
At #EASD2025, the updated EASD-ADA draft #consensusreport on managing #type1diabetes in adults was presented.
Submit your comments by 16 October 2025 at 23:59 ET 👉 professional.diabetes.org/clinical-sup...
🗣️ Listen in as EASD President, Prof. Chantal Mathieu discusses the MELD-ATG #Trial results on antithymocyte globulin in 5-25 y/o with #t1d, presented at #EASD2025 in Vienna.
📖Published in @thelancet.com : www.thelancet.com/journals/lan...
🎥Full interview: www.springermedicine.com/type-1-diabe...
From #EASD2025 - Profs Jane Speight & Richard Holt discuss the importance of the launch of the first draft of the EASD clinical practice guideline on the assessment & management of distress in adults with type 1 or type 2 #diabetes.
Watch now 👉 buff.ly/75J652i
#DiabetesSky #MedSky
From #EASD2025 - Treatment with sustained-release #verapamil has failed to show statistically significant beta cell preservation versus placebo in people newly diagnosed with type 1 #diabetes.
Full story 👉 buff.ly/MuaXHym
#MedNews
From #EASD2025 - Profs Jane Speight & Richard Holt discuss the importance of the launch of the first draft of the EASD clinical practice guideline on the assessment & management of distress in adults with type 1 or type 2 #diabetes.
Watch now 👉 buff.ly/sxRkwHW
#MedSky #DiabetesSky
🥁New #DiabetesPerspectives w. Profs Richard Holt, @janespeight.bsky.social & Michelle Law: Decoding the first-ever EASD guideline on #diabetesdistress🎯 evidence-based strategies for the emotional side of living w. #diabetes presented at #EASD2025.
📺 Watch: bit.ly/46NOrmU
✍️ Comment: bit.ly/46MB8TY
Desde #EASD2025 nos ofrecen un trabajo en el que se planteará si
🦹♂️ ¿El glucagón sigue siendo el malo de la película?
Glucagon: No longer the bad guy in diabetes?
Comentario del Dr. @carlos_teixi
En el #BlogdeMateu
redgedaps.blogspot.com/2025/09/easd-2…
From #EASD2025 - Treatment with #tirzepatide significantly reduces bodyweight and insulin dose versus placebo in people with type 1 #diabetes and #obesity, suggests the TIRTLE1 trial.
Full story 👉 buff.ly/dtY6MXa
#MedNews
🚨 New Journal launched at #EASD2025 in Vienna! Introducing @metabologiajnl.bsky.social - sister journal to @diabetologiajnl.bsky.social, peer-reviewed, open-access, obesity & metabolic health; from basic science to clinical trials, reviews & even negative findings.
Learn more 👉 metabologia.org
Diabète de type 1 : le temps du dépistage en population générale est venu, déclare l’EASD #EASD2025
ms.spr.ly/63329st7HR
From #EASD2025 - Prof. Tamara Hannon talks through the results of the phase 3 SURPASS-PEDS trial showing sustained glycemic and BMI benefits for children and adolescents with type 2 #diabetes.
Watch the full interview 👉 buff.ly/WArMG3H
#T2D #DiabetesSky
From #EASD2025 - #Tirzepatide is noninferior to #dulaglutide for protecting against cardiovascular events in people with type 2 #diabetes and atherosclerotic cardiovascular disease.
Full story 👉 buff.ly/dlX26Xw
#MedNews
En el #EASD2025 un relevante tema
💢 Demencia en personas con diabetes: motivos para tener esperanza o preocupación.
Dementia in diabetes: reasons for hope or concern
✒️ Comentado por Dr. @maruizquintero en #BlogdeMateu
redgedaps.blogspot.com/2025/09/easd-2…
From #EASD2025 - #Orforglipron significantly reduces bodyweight in people with #obesity and significantly lowers glycated hemoglobin levels in those with type 2 #diabetes.
Full story 👉 buff.ly/eh6dfg4
#MedNews
From #EASD2025 - Prof. Chantal Mathieu shares the results of the MELD-ATG trial demonstrating that a low dose of antithymocyte globulin reduces loss of beta cell function in patients aged 5-25 years old who have a recent diagnosis of stage 3 #T1D.
👉 buff.ly/iYjhL6i
#MedSky #DiabetesSky
En #EASD2025 sigue con interesantes artículos:
⭕️ Incidencia de neuropatía óptica isquémica anterior no arterítica (NOIA-NA) con arGLP1
Incidence of NOIA-NA completed phase 2, 3 and 4 trials evaluating arGLP1
Comentario @JoanBarrot en #BlogdeMateu
redgedaps.blogspot.com/2025/09/easd-2…
#EASD2025 Comparación de TIRZE con DULA en MACE para DM2. SURPASS-CVOT
Comparison of TIRZE and DULA on MACE in participants with DM2 and atherosclerotic cardiovascular disease: SURPASS-CVOT.
Comentario del Dr. @JoanBarrot en #BlogdeMateu
redgedaps.blogspot.com/2025/09/easd-2…
